Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06832410 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney Transplant

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 23, 2026 (before its estimated September 17, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Re-verified, no change to tracked fieldsv8
  2. Study sites: 4 to 7v7
  3. Eligibility criteria expanded, about 9 wordsv6 See this version in full on ClinicalTrials.gov ↗
  4. Study sites: 3 to 4v5
  5. Study sites: 2 to 3 Secondary endpoints: details revised at 2 of 4 entriesv4 Show 1 more changeShow less
    • Secondary endpoints: details revised at 2 of 4 entries
Show 2 earlier versionsHide 2 earlier versions
  1. Phase: Phase 2 to Phase 3 Primary completion date: Sep 30, 2026 to Sep 17, 2026 · Completion date: Sep 30, 2030 to Sep 17, 2027 · Start date changed from estimate of Mar 2025 to Mar 31, 2025 · 2 morev3 Show 5 more changesShow less
    • Primary completion date: Sep 30, 2026 to Sep 17, 2026
    • Completion date: Sep 30, 2030 to Sep 17, 2027
    • Start date changed from estimate of Mar 2025 to Mar 31, 2025
    • Secondary endpoints revised (4)
    • Study sites revised (2)

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 2 · Start date: Feb 26, 2025 to Mar 2025v2 Show 2 more changesShow less
    • Study sites: 0 to 2
    • Start date: Feb 26, 2025 to Mar 2025
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Trial Details
NCT Number NCT06832410
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Type 1 Diabetes, Kidney Transplant
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov